Jefferies Financial Group assumed coverage on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a report released on Thursday, Briefing.com reports. The brokerage issued a buy rating and a $15.00 price objective on the stock.
Separately, HC Wainwright upped their price target on Tempest Therapeutics from $35.00 to $47.00 and gave the company a buy rating in a report on Wednesday, October 11th.
Tempest Therapeutics Price Performance
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.07. Research analysts anticipate that Tempest Therapeutics will post -1.93 EPS for the current year.
Institutional Investors Weigh In On Tempest Therapeutics
Several large investors have recently modified their holdings of TPST. Susquehanna International Group LLP bought a new stake in shares of Tempest Therapeutics in the 1st quarter valued at approximately $26,000. Millennium Management LLC bought a new stake in shares of Tempest Therapeutics in the 2nd quarter valued at approximately $29,000. Worth Venture Partners LLC bought a new stake in shares of Tempest Therapeutics in the 2nd quarter valued at approximately $129,000. Geode Capital Management LLC grew its stake in shares of Tempest Therapeutics by 52.9% in the 2nd quarter. Geode Capital Management LLC now owns 102,244 shares of the company’s stock valued at $130,000 after purchasing an additional 35,372 shares during the period. Finally, Renaissance Technologies LLC grew its position in Tempest Therapeutics by 290.2% during the 2nd quarter. Renaissance Technologies LLC now owns 103,401 shares of the company’s stock worth $131,000 after acquiring an additional 76,901 shares during the last quarter. 28.73% of the stock is currently owned by institutional investors.
About Tempest Therapeutics
Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
- Five stocks we like better than Tempest Therapeutics
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- How to use options to collect rent on stocks without owning them
- Election Stocks: How Elections Affect the Stock Market
- Are these frigid Dow stocks in for a longer winter?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Can financial, healthcare, energy stocks rise as rates stay high?
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.